Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
.webp)
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Libtayo (cemiplimab-rwlc) is a PD-1 blocking antibody used across several skin cancers and non-small cell lung cancer, helping the immune system recognize and attack tumor cells.
Libtayo is FDA-approved for metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) not eligible for curative surgery or radiation, and for adjuvant treatment of CSCC at high risk of recurrence after surgery and radiation. It is also approved for locally advanced basal cell carcinoma previously treated with (or not appropriate for) a hedgehog pathway inhibitor, and for first-line NSCLC, either alone in tumors with high PD-L1 expression or combined with platinum-based chemotherapy.
Cemiplimab binds to PD-1 receptors on T-cells, blocking their interaction with PD-L1/PD-L2 on tumor cells, restoring the immune system's ability to identify and destroy cancer cells.
The typical dose is 350 mg by intravenous infusion every 3 weeks, or 700 mg every 6 weeks for certain indications, continued until disease progression or unacceptable toxicity, as determined by the treating oncologist.
As a PD-1 immune checkpoint inhibitor, Libtayo can cause immune-mediated adverse reactions affecting multiple organ systems, which may be severe or fatal and can occur even after treatment discontinuation.
Monitor for new or worsening respiratory symptoms; manage with corticosteroids and treatment interruption as needed.
Monitor for diarrhea or signs of colitis.
Monitor liver function tests and thyroid/adrenal hormone levels periodically; adrenal insufficiency has been reported.
Monitor kidney function and for skin changes throughout treatment.
Monitor during and after infusion for hypersensitivity reactions.
Libtayo can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Libtayo (cemiplimab-rwlc) is manufactured by Regeneron Pharmaceuticals and co-marketed with Sanofi, approved across cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
Import of Libtayo through a Named Patient Program requires a valid prescription from the treating oncologist, diagnosis and treatment history documentation, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Libtayo directly from Regeneron's authorized supply chain to ensure product authenticity and regulatory compliance.
Libtayo is sourced through verified, GDP-compliant, cold-chain channels from Regeneron's authorized supply chain to ensure authenticity and quality.
Libtayo should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Libtayo is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Libtayo through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading oncology centers in Mumbai support skin cancer and lung cancer treatment coordination for Libtayo access.
Delhi's major cancer hospitals assist patients with treatment planning and prescription support for Libtayo.
Bangalore's oncology network offers access to Libtayo for eligible patients.
Chennai-based specialists coordinate Libtayo access alongside comprehensive cancer care.
Hyderabad's cancer care institutions support patients pursuing Libtayo therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Libtayo.
Pune-based oncologists assist with treatment planning for Libtayo.
Ahmedabad's specialty hospitals support the import and treatment process for Libtayo.
Kochi's oncology units assist patients with the documentation needed for Libtayo access.
Chandigarh's cancer care centers support Libtayo treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Libtayo access process.
Lucknow-based cancer centers assist patients pursuing Libtayo therapy.
Bhubaneswar's oncology institutions support access to Libtayo for eligible patients.
Guwahati's specialists help coordinate Libtayo access for patients across the Northeast.
Patients in other cities across India can also access Libtayo through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
